Brazilian study investigates why some HIV patients fail key drug combo

NCT ID NCT04453436

Ongoing Knowledge-focused Sponsor: Federal University of São Paulo Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tracks 2,500 people with HIV in Brazil who are taking a common first-line treatment (tenofovir/lamivudine and dolutegravir) to see why some develop drug resistance. Researchers will test blood samples from those whose viral load remains detectable to look for resistance mutations. The goal is to gather real-world data to improve HIV care in similar settings.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this study could help doctors understand why some people develop drug resistance to common HIV medications, potentially improving future treatment guidelines.
What could go wrong: This is an observational study, not a treatment trial. It only looks at people who have already failed therapy, so it cannot predict who will fail or test new treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRUG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

drug dependence HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DRUG HIV RESISTANCE

Contacts and locations

Locations

Laboratório de Retrovirologia, EP2

São Paulo, São Paulo, 04039-032, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.